Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Other Accumulated Expenses (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Other Accumulated Expenses readings, the most recent being $270000.0 for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 800.0% to $270000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $270000.0, a 800.0% increase, with the full-year FY2024 number at $172000.0, up 290.91% from a year prior.
  • Other Accumulated Expenses hit $270000.0 in Q3 2025 for Arcadia Biosciences, roughly flat from $270000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $298000.0 in Q4 2022 to a low of $30000.0 in Q3 2024.
  • Median Other Accumulated Expenses over the past 5 years was $264000.0 (2021), compared with a mean of $203222.2.
  • Biggest five-year swings in Other Accumulated Expenses: plummeted 87.87% in 2023 and later skyrocketed 800.0% in 2025.
  • Arcadia Biosciences' Other Accumulated Expenses stood at $264000.0 in 2021, then rose by 12.88% to $298000.0 in 2022, then crashed by 85.23% to $44000.0 in 2023, then skyrocketed by 290.91% to $172000.0 in 2024, then skyrocketed by 56.98% to $270000.0 in 2025.
  • The last three reported values for Other Accumulated Expenses were $270000.0 (Q3 2025), $270000.0 (Q1 2025), and $172000.0 (Q4 2024) per Business Quant data.